Based on the TransMedics Group Inc stock forecast from 9 analysts, the average analyst target price for TransMedics Group Inc is USD 163.39 over the next 12 months. TransMedics Group Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of TransMedics Group Inc is Neutral, which is based on 7 positive signals and 6 negative signals. At the last closing, TransMedics Group Inc’s stock price was USD 88.36. TransMedics Group Inc’s stock price has changed by +3.35% over the past week, -34.18% over the past month and +36.34% over the last year.
No recent analyst target price found for TransMedics Group Inc
No recent average analyst rating found for TransMedics Group Inc
Company Overview TransMedics Group Inc
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts. Read Less
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimiza...Read More
Frequently Asked Questions About TransMedics Group Inc (TMDX) Stock
Based on ratings from 9 analysts TransMedics Group Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 20 buy, sell and 3 hold ratings.
Unfortunately we do not have enough data on TMDX's stock to indicate if its a good dividend stock.
Based on targets from 9 analysts, the average taret price for TMDX is USD 163.39 over the next 12 months. The maximum analyst target price is USD 208 while the minimum anlayst target price is USD 87.
TMDX stock's Price/Earning ratio is 91.47.
Our analysis grades TMDX stock's Price / Earning ratio at F. This means that TMDX stock's Price/Earning ratio is above 77% of the stocks in the Medical Devices sector in the NSD exchange.
Based on this TMDX may be a overvalued for its sector.
The last closing price of TMDX's stock was USD 88.36.
The most recent market capitalization for TMDX is USD 2.89B.
Based on targets from 9 analysts, the average taret price for TMDX is projected at USD 163.39 over the next 12 months.
This means that TMDX's stock price may go up by +84.92% over the next 12 months.
We can't find any ETFs which contains TransMedics Group Inc's stock.
As per our most recent records TransMedics Group Inc has 584 Employees.
TransMedics Group Inc's registered address is 200 Minuteman Road, Andover, MA, United States, 01810.
You can get more information about it from TransMedics Group Inc's website at https://www.transmedics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About TransMedics Group Inc (TMDX) Stock
Based on ratings from 9 analysts TransMedics Group Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 20 buy, sell and 3 hold ratings.
Unfortunately we do not have enough data on TMDX's stock to indicate if its a good dividend stock.
Based on targets from 9 analysts, the average taret price for TMDX is USD 163.39 over the next 12 months. The maximum analyst target price is USD 208 while the minimum anlayst target price is USD 87.
TMDX stock's Price/Earning ratio is 91.47.
Our analysis grades TMDX stock's Price / Earning ratio at F. This means that TMDX stock's Price/Earning ratio is above 77% of the stocks in the Medical Devices sector in the NSD exchange.
Based on this TMDX may be a overvalued for its sector.
The last closing price of TMDX's stock was USD 88.36.
The most recent market capitalization for TMDX is USD 2.89B.
Based on targets from 9 analysts, the average taret price for TMDX is projected at USD 163.39 over the next 12 months.
This means that TMDX's stock price may go up by +84.92% over the next 12 months.
We can't find any ETFs which contains TransMedics Group Inc's stock.
As per our most recent records TransMedics Group Inc has 584 Employees.
TransMedics Group Inc's registered address is 200 Minuteman Road, Andover, MA, United States, 01810.
You can get more information about it from TransMedics Group Inc's website at https://www.transmedics.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for TMDX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
